追风透骨胶囊结合骨肽注射液改善骨质疏松症腰腿痛的临床观察

Clinical Observation of Zhuifeng Tougu Capsule Combined with Ossotide Injection in Improving Lumbocrural Pain in Osteoporosis

目的探讨追风透骨胶囊结合骨肽注射液对骨质疏松症腰腿痛的改善效果及安全性。方法选取骨质疏松症患者150例,按照随机数字表法分为对照组和观察组,各75例。对照组患者采取骨肽注射液治疗,观察组在对照组基础上加用追风透骨胶囊治疗。比较2组临床疗效、治疗前后视觉模拟评分(VAS)和功能障碍指数(ODI)评分、骨代谢生化指标[骨钙素(BGP)、骨特异性碱性磷酸酶(BALP)、抗酒石酸盐酸性磷酸酶(TRAP)、骨保护素(OPG)及胰岛素样生长因子-1(IGF-1)]水平变化、骨密度值及不良反应情况。结果观察组总有效率97.33%,高于对照组88.00%,差异有统计学意义(P<0.05)。治疗前2组VAS、ODI评分比较,差异无统计学意义(P>0.05);治疗后,对照组VAS、ODI评分分别为(4.85±0.67)分、(25.84±5.11)分,观察组分别为(4.32±0.55)分、(20.63±4.47)分,2组评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗前2组患者的BGP、BALP、OPG及IGF-1水平比较,差异无统计学意义(P>0.05);治疗后2组患者的BGP、BALP、OPG及IGF-1水平均较治疗前增加,且观察组高于对照组,差异有统计学意义(P<0.05);对照组和观察组TRAP的水平分别为(9.74±3.02)μg·L^(-1)、(8.18±2.86)μg·L^(-1),均较治疗前下降,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗后,对照组和观察组患者的腰椎和股骨近端的骨密度值分别为(0.79±0.13)g·cm^(-2)、(0.74±0.09)g·cm^(-2)和(0.83±0.11)g·cm^(-2)及(0.78±0.13)g·cm^(-2),均较治疗前提高,且观察组高于对照组,差异有统计学意义(P<0.05)。观察组不良反应总发生率7.99%,对照组为9.33%,差异无统计学意义(P>0.05)。结论追风透骨胶囊结合骨肽注射液能够改善患者骨代谢指标,使骨密度值增加,缓解骨质疏松症腰腿痛症状,临床疗效及安全性较好。

Objective To investigate the improvement effects and safety analysis of Zhuifeng Tougu capsule combined with ossotide injection on lumbocrural pain in osteoporosis.Methods 150 cases of osteoporosis patients were selected,and they were divided into control group and observation group by random number table,75 cases in each group.Control group was treated with ossotide injection,and observation group were treated with Zhuifeng Tougu capsule orally on the basis of control group,and the two groups were treated continuously.The clinical efficacy,and visual analogue score(VAS)and Oswestry disability index(ODI),biochemical markers of bone metabolism[bone gla protein(BGP),bone-specific alkaline phosphatase(BALP),tartrate resistant acid phosphatase(TRAP),osteoprotegerin(OPG)and insulin-like growth factor-1(IGF-1),bone mineral density value and adverse reactions before and after treatment were compared between the two groups.Results After treatment,the total effective rate of the observation group was 97.33%,which was higher than 88.00%of the control group,and the difference was statistically significant(P<0.05).Before treatment,the VAS and ODI scores of the two groups were not statistically different(P>0.05);after treatment,the VAS and ODI scores of the control group were(4.85±0.67)and(25.84±5.11)points,respectively,and the observation group were respectively(4.32±0.55)points,(20.63±4.47)points,the scores of the two groups were higher than those before treatment,and the observation group was lower than the control group,the difference was statistically significant(P<0.05).Before treatment,the levels of BGP,BALP,OPG and IGF-1 in the two groups were not statistically different(P>0.05);after treatment,the levels of BGP,BALP,OPG,and IGF-1 in the two groups were higher than those of the treatment,the level of TRAP in the control group and the observation group was(9.74±3.02)μg·L^(-1) and(8.18±2.86)μg·L^(-1),all decreased compared with before treatment,and the observation group was lower than the control group,the difference was statistically significant(P<0.05).After treatment,the bone mineral density values of the lumbar spine and proximal femur of the control group and observation group were(0.79±0.13)g·cm^(-2),(0.74±0.09)g·cm^(-2) and(0.83±0.11)g·cm^(-2) and(0.78±0.13)g·cm^(-2) were both higher than before treatment,and the observation group was higher than the control group,the difference was statistically significant(P<0.05).The total incidence of adverse reactions was 7.99%in the observation group and 9.33%in the control group,and the difference was not statistically significant(P>0.05).Conclusion Zhuifeng Tougu capsule combined with ossotide injection can significantly improve bone metabolism indexes and increase bone mineral density,relieve low back pain symptoms of osteoporosis,and it has significant clinical efficacy and good safety.Thus it is worthy of popularization and application.